US Patent

US8377921 — Compounds and compositions as protein kinase inhibitors

Method of Use · Assigned to IRM LLC · Expires 2027-11-20 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel pyrimidine and pyridine derivatives and their pharmaceutical compositions, which can be used to treat conditions that respond to inhibition of certain protein kinases.

USPTO Abstract

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1179 — Zykadia
U-1179 — Zykadia

Patent Metadata

Patent number
US8377921
Jurisdiction
US
Classification
Method of Use
Expires
2027-11-20
Drug substance claim
No
Drug product claim
No
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.